The Manufacturers Life Insurance Company Buys 134,028 Shares of Iovance Biotherapeutics, Inc. $IOVA

Posted by on Aug 12th, 2026

The Manufacturers Life Insurance Company lifted its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 57.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 365,471 shares of the biotechnology company’s stock after purchasing an additional 134,028 shares during the period. The Manufacturers Life Insurance Company owned 0.08% of Iovance Biotherapeutics worth $1,283,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Arcataur Capital Management LLC purchased a new position in Iovance Biotherapeutics in the fourth quarter valued at approximately $29,000. Granite Investment Partners LLC bought a new stake in shares of Iovance Biotherapeutics in the fourth quarter valued at $29,000. Motley Fool Asset Management LLC bought a new stake in shares of Iovance Biotherapeutics in the fourth quarter valued at $29,000. M&T Bank Corp purchased a new position in shares of Iovance Biotherapeutics during the 4th quarter valued at $31,000. Finally, SBI Securities Co. Ltd. lifted its position in shares of Iovance Biotherapeutics by 169.1% during the 4th quarter. SBI Securities Co. Ltd. now owns 11,568 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 7,269 shares during the last quarter. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Stock Up 1.4%

IOVA stock opened at $6.49 on Wednesday. The firm has a market capitalization of $2.94 billion, a PE ratio of -8.89 and a beta of 0.71. Iovance Biotherapeutics, Inc. has a twelve month low of $1.76 and a twelve month high of $6.92. The stock has a 50-day simple moving average of $4.50 and a two-hundred day simple moving average of $3.87.

Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. Iovance Biotherapeutics had a negative return on equity of 40.92% and a negative net margin of 89.11%.The firm had revenue of $198.63 million for the quarter, compared to analysts’ expectations of $87.83 million. During the same period in the prior year, the business posted ($0.33) earnings per share. The company’s revenue was up 65.7% on a year-over-year basis. On average, equities research analysts anticipate that Iovance Biotherapeutics, Inc. will post -0.56 EPS for the current fiscal year.

Analysts Set New Price Targets

IOVA has been the subject of several recent research reports. Barclays lifted their price objective on Iovance Biotherapeutics from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Friday. Chardan Capital cut their target price on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Robert W. Baird set a $6.00 target price on shares of Iovance Biotherapeutics in a research note on Friday. Citigroup reissued an “outperform” rating on shares of Iovance Biotherapeutics in a research report on Friday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Thursday, July 2nd. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $8.00.

Get Our Latest Stock Analysis on Iovance Biotherapeutics

About Iovance Biotherapeutics

(Free Report)

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.

Read More

Want to see what other hedge funds are holding IOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report).

Institutional Ownership by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.